<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        11-399-04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LINOPRIL 10MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LISINOPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Linopril<sup>&reg;</sup> </strong>contains a medicine called lisinopril. This belongs to a group of medicines called ACE inhibitors.</p><p><strong>Linopril<sup>&reg;</sup> </strong>can be used for the following conditions:</p><p>To treat high blood pressure (hypertension).</p><p>To treat heart failure.</p><p>If you have recently had a heart attack (myocardial infarction).</p><p>To treat kidney problems caused by Type II diabetes in people with high blood pressure.</p><p><strong>Linopril<sup>&reg;</sup> </strong>works by making your blood vessels widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Linopril<sup>&reg;</sup>:<sup> </sup></strong></p><p>If you are allergic to lisinopril or any of the other ingredients of this medicine.</p><p>If you have ever had an allergic reaction to another ACE inhibitor medicine. The allergic reaction may have caused itching, hives, sudden fall in blood pressure, swelling of the hands, feet, ankles, face, lips, tongue or throat. It may also have made it difficult to swallow or breathe (angioedema).</p><p>If a member of your family has had severe allergic reactions (angioedema) to an ACE inhibitor or you have had severe allergic reactions (angioedema) without a known cause.</p><p>If you are more than 3 months pregnant. (It is also better to avoid <strong>Linopril<sup>&reg;</sup> </strong>in early pregnancy).</p><p>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking <strong>Linopril<sup>&reg;</sup></strong>.</p><p>If you develop a dry cough which is persistent for a long time after starting treatment with<sup> </sup><strong>Linopril<sup>&reg;</sup></strong>,<sup> </sup>talk to your doctor.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or your pharmacist before taking<strong> Linopril<sup>&reg;</sup>: </strong></p><p>If you have a narrowing (stenosis) of the aorta (an artery in your heart) or a narrowing of the heart valves (mitral valves).</p><p>If you are taking any of the following medicines used to treat high blood pressure:</p><p>- An angiotensin II receptor blocker (ARBs) (also known as sartans &ndash; for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>- Aliskiren.</p><p>- If you are taking medicines called mTOR inhibitors (for example temsirolimus, everolimus, sirolimus) or medicines containing NEP inhibitors (for example racecadotril) as they may increase the risk of angioedema. Signs of angioedema include swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing.</p><p>- Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>If you have a narrowing (stenosis) of the kidney artery.</p><p>If you have an increase in the thickness of the heart muscle (known as hypertrophic cardiomyopathy).</p><p>If you have problems with your blood vessels (collagen vascular disease).</p><p>If you have low blood pressure. You may notice this as feeling dizzy or light-headed, especially when standing up.</p><p>If you have kidney problems or you are having kidney dialysis.</p><p>If you have liver problems.</p><p>If you have diabetes.</p><p>You have recently had diarrhea or vomiting (being sick).</p><p>If you doctor has told you to control the amount of salt in your diet.</p><p>If you have high levels of cholesterol and you are having a treatment called &lsquo;LDL apheresis&rsquo;.</p><p>You must tell your doctor if you think you are (or might become) pregnant. <strong>Linopril<sup>&reg;</sup> </strong>is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p>If you are of black origin as <strong>Linopril<sup>&reg;</sup> </strong>may be less effective. You may also more readily get the side effect &lsquo;angioedema&rsquo; (a severe allergic reaction).</p><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking <strong>Linopril<sup>&reg;</sup></strong>.</p><p><strong>Treatment for allergies such as insect stings</strong></p><p>Tell your doctor if you are having or are going to have treatment to lower the effects of an allergy such as insect stings (desensitization treatment). If you take <strong>Linopril<sup>&reg;</sup> </strong>while you are having this treatment, it may cause a severe allergic reaction.</p><p><strong>Operations</strong></p><p>If you are going to have an operation (including dental surgery) tell the doctor or dentist that you are taking <strong>Linopril<sup>&reg;</sup></strong>. This is because you can get low blood pressure (hypotension) if you are given certain local or general anesthetics while you are taking <strong>Linopril<sup>&reg;</sup></strong>.</p><p><strong>Children and adolescents</strong></p><p>Lisinopril<strong> </strong>has been studied in children. For more information, talk to your doctor. <strong>Linopril<sup>&reg;</sup> </strong>is not recommended in children under 6 years of age or in any child with severe kidney problems.</p><p><strong>Other medicines and Linopril<sup>&reg;</sup></strong></p><p>Tell your doctor if you are taking, have recently taken, or might take any other medicines. This is because <strong>Linopril<sup>&reg;</sup> </strong>can affect the way some medicines work and some medicines can have an effect on <strong>Linopril<sup>&reg;</sup></strong>.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>Other medicines for treatment of high blood pressure (antihypertensives) including an angiotensin II receptor blocker (ARB) or aliskiren.</p><p>Aliskiren containing medicines (for treatment of high blood pressure).</p><p>Water tablets (diuretic medicines).</p><p>Medicines to break up blood clots (usually given in hospital).</p><p>Beta-blocker medicines, such as atenolol and propranolol.</p><p>Nitrate medicines (for heart problems).</p><p>&bull; Non-steroidal anti-inflammatory drugs (NSAIDs) used to treat pain and arthritis.</p><p>&bull; Aspirin (Acetylsalicylic acid), if you are taking more than 3 grams each day.</p><p>&bull; Medicines for depression and for mental problems, including lithium.</p><p>Potassium supplements,&nbsp;substitutes&nbsp;containing potassium or other drugs which can increase potassium in your body.&nbsp;</p><p>Insulin or medicines that you take by mouth for diabetes.</p><p>Medicines to treat cancer (such as everolimus) and medicines given to prevent the body from rejecting a transplanted organ, e.g. kidney or liver (such as temsirolimus, sirolimus).</p><p>Racecadotril used to treat diarrhea.</p><p>Tissue plasminogen activator (TPA) that is used to dissolve blood clots that have formed in blood vessels.</p><p>Medicines used to treat asthma.</p><p>Medicines to treat nose or sinus congestion or other cold remedies (including those you can buy in the pharmacy).</p><p>Medicines to suppress the body&rsquo;s immune response (immunosuppressants).</p><p>Allopurinol (for gout).</p><p>Procainamide (for heart beat problems).</p><p>Medicines that contain gold, such as sodium aurothiomalate, which may be given to you as an injection.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Pregnancy</strong></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking <strong>Linopril<sup>&reg;</sup> </strong>before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of <strong>Linopril<sup>&reg;</sup></strong>.<sup> </sup><strong>Linopril<sup>&reg;</sup> </strong>is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. <strong>Linopril<sup>&reg;</sup> </strong>is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines </strong></p><p>Some people feel dizzy or tired when taking this medicine. If this happens to you, do not drive or use any tools or machines.</p><p>You must wait to see how your medicine affects you before trying these activities.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Linopril<sup>&reg;</sup> </strong>exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Once you have started taking <strong>Linopril<sup>&reg;</sup> </strong>your doctor may take blood tests. Your doctor may then adjust your dose so you take the right amount of medicine for you.</p><p><strong>Taking your medicine</strong></p><p>Swallow the tablet with a drink of water.</p><p>Try to take your tablets at the same time each day. It does not matter if you take <strong>Linopril<sup>&reg;</sup> </strong>before or after food.</p><p>Keep taking <strong>Linopril<sup>&reg;</sup> </strong>for as long as your doctor tells you to, it is a long term treatment. It is important to keep taking <strong>Linopril<sup>&reg;</sup> </strong>every day.</p><p><strong>Taking your first dose</strong></p><p>Take special care when you have your first dose of <strong>Linopril<sup>&reg;</sup> </strong>or if your dose is increased. It may cause a greater fall in blood pressure than later doses.</p><p>This may make you feel dizzy or light-headed. If this happens, it may help to lie down. If you are concerned, please talk to your doctor as soon as possible.</p><p><strong>Adults</strong></p><p>Your dose depends on your medical condition and whether you are taking any other medicines. Your doctor will tell you how many tablets to take each day. Check with your doctor or pharmacist if you are unsure.</p><p><strong>For high blood pressure</strong></p><p>The recommended starting dose is 10 mg once a day.</p><p>The usual long-term dose is 20 mg once a day.</p><p><strong>For heart failure</strong></p><p>The long-term dose is 5 to 35 mg once a day.</p><p><strong>After a heart attack</strong></p><p>The recommended starting dose is 5 mg within 24 hours of your attack and 5 mg one day later.</p><p>The usual long-term dose is 10 mg once a day.</p><p><strong>For kidney problems caused by diabetes</strong></p><p>The recommended dose is either 10 mg or 20 mg once a day.</p><p>If you are elderly, have kidney problems or are taking diuretic medicines your doctor may give you a lower dose than the usual dose.</p><p><strong>Use in children and adolescents (6 to 16 years old) with high blood pressure</strong></p><p><strong>Linopril<sup>&reg;</sup> </strong>is not recommended for children under 6 years or in any children with severe kidney problems.</p><p>The doctor will work out the correct dose for your child. The dose depends on the child&rsquo;s body weight.</p><p>For children who weigh more than 50 kg, the recommended starting dose is 5 mg once a day.</p><p><strong>If you take more Linopril<sup>&reg;</sup> than you should</strong></p><p>If you take more <strong>Linopril<sup>&reg;</sup> </strong>than prescribed by your doctor, talk to a doctor or go to a hospital immediately. The following effects are most likely to happen: Dizziness, palpitations.</p><p><strong>If you forget to take Linopril<sup>&reg; </sup></strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Linopril<sup>&reg;</sup> </strong></p><p>Do not stop taking your tablets, even if you are feeling well, unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Linopril<sup>&reg; </sup></strong>can cause side effects, although not everybody gets them.</p><p><strong>If you experience any of the following reactions, stop taking Lisinopril and see your doctor immediately: </strong></p><p>Severe allergic reactions (rare, affects 1 to 10 users in 10,000). The signs may include sudden onset of:</p><p>- Swelling of your face, lips, tongue or throat. This may make it difficult to swallow.</p><p>- Severe or sudden swelling of your hands, feet and ankles.</p><p>- Difficulty breathing.</p><p>- Severe itching of the skin (with raised lumps).</p><p>Severe skin disorders, like a sudden, unexpected rash or burning, red or peeling skin (very rare, affects less than 1 user in 10,000).</p><p>An infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems (very rare, affects less than 1 user in 10,000).</p><p><strong>Other possible side effects:</strong></p><p><strong>Common (affects 1 to 10 users in 100) </strong></p><p>Headache.</p><p>Feeling dizzy or light-headed, especially if you stand up quickly.</p><p>Diarrhea.</p><p>A dry cough that does not go away.</p><p>Being sick (vomiting).</p><p>Kidney problems (shown in a blood test).</p><p><strong>Uncommon (affects 1 to 10 users in 1,000) </strong></p><p>Mood changes.</p><p>Change of color in your fingers or toes (pale blue followed by redness) or numbness or tingling in your fingers or toes.</p><p>Changes in the way things taste.</p><p>Feeling sleepy.</p><p>Spinning feeling (vertigo).</p><p>Having difficulty sleeping.</p><p>Stroke.</p><p>Fast heartbeat.</p><p>Runny nose.</p><p>Feeling sick (nausea).</p><p>Stomach pain or indigestion.</p><p>Skin rash or itching.</p><p>Being unable to get an erection (impotence).</p><p>Feeling tired or feeling weak (loss of strength).</p><p>A very big drop in blood pressure may happen in people with the following conditions:</p><p>Coronary heart disease; narrowing of the aorta (a heart artery), kidney artery or heart valves; an increase in the thickness of the heart muscle. If this happens to you, you may feel dizzy or light-headed, especially if you stand up quickly.</p><p>Changes in blood tests that show how well your liver and kidneys are working.</p><p>Heart attack.</p><p>Seen and/or heard hallucinations.</p><p><strong>Rare (affects 1 to 10 users in 10,000) </strong></p><p>Feeling confused.</p><p>A lumpy rash (hives).</p><p>Dry mouth.</p><p>Hair loss.</p><p>Psoriasis (a skin problem).</p><p>Changes in the way things smell.</p><p>Development of breasts in men.</p><p>Changes to some of the cells or other parts of your blood. Your doctor may take blood samples from time to time to check whether lisinopril<strong> </strong>has had any effect on your blood. The signs may include feeling tired, pale skin, a sore throat, high temperature (fever), joint and muscle pains, swelling of the joints or glands, or sensitivity to sunlight.</p><p>Low levels of sodium in your blood (the symptoms may be tiredness, headache, nausea, vomiting).</p><p>Sudden renal failure.</p><p><strong>Very rare (affect less than 1 user in 10,000) </strong></p><p>Sinusitis (a feeling of pain and fullness behind your cheeks and eyes).</p><p>Wheezing.</p><p>Low levels of sugar in your blood (hypoglycaemia). The signs may include feeling hungry or weak, sweating and a fast heartbeat.</p><p>Inflammation of the lungs. The signs include cough, feeling short of breath and high temperature (fever).</p><p>Yellowing of the skin or the whites of the eyes (jaundice).</p><p>Inflammation of the liver. This can cause loss of appetite, yellowing of the skin and eyes, and dark colored urine.</p><p>Inflammation of the pancreas. This causes moderate to severe pain in the stomach.</p><p>Severe skin disorders. The symptoms include redness, blistering and peeling.</p><p>Sweating.</p><p>Passing less water (urine) than normal or passing no water.</p><p>Liver failure.</p><p>Lumps.</p><p>Inflamed gut.</p><p><strong>Not known (frequency cannot be estimated from available data)</strong></p><p>Symptoms of depression.</p><p>Fainting.</p><p>&bull; Serious allergic reaction.</p><p>Side effects in children appear to be comparable to those seen in adults.</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. </strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Linopril<sup>&reg;</sup> </strong>tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Linopril<sup>&reg;</sup> </strong>tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed via waste water or household waste. Ask your pharmacist how to dispose medicines no longer required. This will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Lisinopril (as dihydrate).</p><p>The other ingredients are mannitol, calcium hydrogen phosphate, maize starch, pregelatinised starch, magnesium stearate, red iron oxide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Linopril® 5mg Tablets: Light red brick, round, normal convex tablet engraved with PhI on one face and scored on the other, packed in PVC/ Alu blisters, intended for oral use.
Pack size: 28 Tablets (14 tablets/blister, 2 blisters/pack).
Linopril® 10mg Tablets: Red brick, round, normal convex tablet engraved with PhI on one face and scored on the other, packed in PVC/ Alu blisters, intended for oral use.
Pack size: 28 Tablets (14 tablets/blister, 2 blisters/pack).
Linopril® 20mg Tablets: Red brick, round; normal convex tablets engraved with PhI on one side and plain on the other, packed in PVC/ Alu blisters, intended for oral use.
Pack size: 28 Tablets (14 tablets/blister, 2 blisters/pack).

To report any side effect(s):
•Saudi Arabia:
The National Pharmacovigilance Center (NPC):
SFDA Call Center: 19999 
E-mail: npc.drug@sfda.gov.sa 
Website: https://ade.sfda.gov.sa
•United Arab of Emirates:
Pharmacovigilance and Medical Device Section
P.O. Box: 1853, Tel: 80011111
Email: pv@mohap.gov.ae
Drug Department, Ministry of Health & Prevention
Dubai-UAE.
•Other GCC States:
Please contact the relevant competent authority.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharma International Company</p><p>Amman - Jordan</p><p>Tel: 00962-6-5158890 / 5157893</p><p>Fax: 00962-6-5154753</p><p>Email: marketing@pic-jo.com</p><p>&nbsp;</p><p>This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong> على دواء يسمى ليزينوبريل. والذي ينتمي إلى مجموعة من الأدوية تسمى مثبطات الإنزيم المحول للأنجيوتنسين.</p><p dir="RTL">يمكن أن يستعمل <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong> في الحالات التالية:</p><p dir="RTL">لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">لعلاج قصور وظيفة عضلة القلب.</p><p dir="RTL">إذا تعرضت مؤخراً لنوبة قلبية (احتشاء عضلة القلب).</p><p dir="RTL">لعلاج مشاكل الكلى الناتجة عن داء السكري النوع الثاني عند الأشخاص الذين يعانون من ارتفاع ضغط الدم.</p><p dir="RTL">يعمل <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong> على توسيع الأوعية الدموية. هذا يساعد على تخفيض ضغط الدم. مما يسهل أيضا على القلب عملية ضخ الدم لجميع أجزاء الجسم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">إذا كنت تعاني من تحسس لليزينوبريل أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL">إذا عانيت سابقا من تفاعل تحسسي لأي من أدوية مثبطات الإنزيم المحول للأنجيوتنسين الأخرى. قد يسبب التفاعل التحسسي حكة، شرى، انخفاض مفاجيء في ضغط الدم، تورم في اليدين، القدمين، الكاحلين، الوجه، الشفاه، اللسان أو الحلق. قد يؤدي أيضا لصعوبة في البلع أو التنفس (وذمة وعائية).</p><p dir="RTL">إذا عانى أحد أفراد عائلتك سابقا من تفاعل تحسسي حاد (وذمة وعائية) لأي من مثبطات الإنزيم المحول للأنجيوتنسين أو عانيت سابقا من تفاعل تحسسي حاد (وذمة وعائية) بدون معرفة السبب.</p><p dir="RTL">إذا كان عمر الحمل يزيد عن 3 أشهر (من الأفضل أيضاً تجنب <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>في المراحل الأولى من الحمل).</p><p dir="RTL">إذا كنت تعاني من داء السكري أو قصور وظيفة الكلى و يتم علاجك باستعمال دواء خافض لضغط الدم يحتوي على أليسكرين.</p><p dir="RTL">إذا لم تكن متاكدا إذا كان أي مما سبق ينطبق عليك. تحدث مع طبيبك أو الصيدلي قبل تناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">إذا عانيت من سعال جاف يستمر لفترات طويلة بعد العلاج باستعمال <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>، تحدث مع طبيبك.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>و</strong><strong> </strong><strong>المحاذير</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong><strong>&nbsp;</strong>في الحالات التالية:</p><p dir="RTL">إذا كنت تعاني من تضيق في الشريان الأبهري (شريان في القلب) أو تضيق في صمامات القلب (الصمامات التاجية).</p><p dir="RTL">إذا كنت تتناول أي من الأدوية التالية التي تستعمل لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">- حاصرات مستقبلات أنجيوتنسين II (تعرف أيضا بالسارتان - على سبيل المثال ڤالسارتان، تيلميسارتان، إربيسارتان)، خصوصا إذا كنت تعاني من مشاكل في الكلى مرتبطة بداء السكري.</p><p dir="RTL">- أليسكرين.</p><p dir="RTL">إذا كنت تتناول أدوية تعرف بمثبطات هدف الثدييات من الراباميسين (على سبيل المثال، تيمسيروليمس، إيڤيروليمس، سيروليمس) أو الأدوية التي تحتوي على مثبطات&nbsp;النيبريلين&nbsp;(على سبيل المثال، راسيكادوتريل) حيث قد تزيد من خطر الإصابة بالوذمة الوعائية.</p><p dir="RTL">تتضمن علامات الوذمة الوعائية، تورم الوجه، الشفاه، اللسان و/أو الحلق يرافقه صعوبة في البلع أو التنفس.</p><p dir="RTL">- قد يقوم طبيبك بالتأكد من وظائف الكلى، ضغط الدم، و كمية الكهرليات (مثل، البوتاسيوم) في الدم على فترات منتظمة.</p><p dir="RTL">إذا كنت تعاني من تضيق في الشريان الكلوي.</p><p dir="RTL">إذا كنت تعاني من زيادة في سماكة عضلة القلب (يعرف باعتلال عضلة القلب الضخامي).</p><p dir="RTL">إذا كنت تعاني من مشاكل في الأوعية الدموية (مرض الكولاجين الوعائي).</p><p dir="RTL">إذا كنت تعاني من انخفاض ضغط الدم. قد تلاحظ هذا على شكل الشعور بالدوار أو الدوخة خاصة عند الوقوف.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى أو تخضع للديلزة الكلوية.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد.</p><p dir="RTL">إذا كنت تعاني من داء السكري.</p><p dir="RTL">إذا عانيت مؤخراً من الإسهال أو القيء.</p><p dir="RTL">إذا أخبرك طبيبك بضرورة ضبط كمية الملح في نظامك الغذائي.</p><p dir="RTL">إذا كنت تعاني من ارتفاع مستوى الكوليسترول و كنت تخضع لعلاج يسمى عملية فصل البروتين الدهني منخفض الكثافة من الدم.</p><p dir="RTL">يجب إخبار طبيبك إذا كنت تعتقدين بأنك حامل (قد تصبحين حامل). لا يوصى باستعمال <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>&nbsp;في المراحل الأولى من الحمل، و يجب عدم استعماله إذا كان عمر الحمل يزيد عن ثلاثة أشهر، حيث قد يسبب أذى خطير على طفلك في حال استعماله في تلك المرحلة.</p><p dir="RTL">قد يكون <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>أقل فعالية إذا كنت من أصل ذوي البشرة السوداء. قد تكون أيضا أكثر عرضة للأثر الجانبي &ldquo;وذمة وعائية&rdquo; (تفاعل تحسسي حاد).</p><p dir="RTL">إذا لم تكن متأكدا إذا كان أي مما ذكر في الأعلى ينطبق عليك، تحدث مع طبيبك أو الصيدلي قبل تناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>علاج</strong><strong> </strong><strong>التحسس</strong><strong> </strong><strong>مثل</strong><strong> </strong><strong>لسعات</strong><strong> </strong><strong>الحشرات</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تخضع أو ستخضع لعلاج لخفض تأثيرات الحساسية مثل لسع الحشرات (علاج إزالة التحسس). إذا كنت تتناول <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>أثناء خضوعك لهذا العلاج، هذا قد يسبب تفاعل تحسسي حاد.</p><p dir="RTL"><strong>العمليات</strong><strong> </strong><strong>الجراحية</strong></p><p dir="RTL">إذا كنت ستخضع لعملية جراحية (بما في ذلك عملية جراحية في الأسنان) أخبر طبيبك أو طبيب الأسنان بأنك تتناول<strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>. وذلك لأنك قد تعاني من انخفاض ضغط الدم إذا تم إعطاؤك نوع معين من المخدر الموضعي أو العام أثناء تناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">تم دراسة تأثير<strong> </strong>ليزينوبريل<strong> </strong>على الأطفال. للمزيد من المعلومات، يرجى مراجعة طبيبك.</p><p dir="RTL">لا يوصى باستعمال <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>للأطفال الذين تقل أعمارهم عن 6 سنوات أو لأي طفل يعاني من مشاكل حادة في الكلى.</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو من الممكن أن تتناول أي أدوية أخرى. و ذلك لأن <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>قد يؤثر على طريقة عمل الأدوية الأخرى و بعض الأدوية قد يكون لها تأثير على <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>.<strong><sup> </sup></strong></p><p dir="RTL">خصوصا، أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">الأدوية الأخرى التي تستعمل لعلاج ارتفاع ضغط الدم، بما في ذلك حاصرات مستقبلات أنجيوتنسين II أو أليسكرين.</p><p dir="RTL">الأدوية التي تحتوي على أليسكرين (لعلاج ارتفاع ضغط الدم).</p><p dir="RTL">أقراص الماء (مدرات البول).</p><p dir="RTL">الأدوية التي تستعمل لتفكيك الجلطات الدموية (تعطى عادة في المستشفى).</p><p dir="RTL">أدوية حاصرات بيتا، مثل أتينولول و بروبانولول.</p><p dir="RTL">أدوية النايتريت (لعلاج مشاكل القلب).</p><p dir="RTL">الأدوية غير الستيرويدية المضادة للالتهاب تستعمل لعلاج الألم و التهاب المفاصل.</p><p dir="RTL">أسبرين (أسيتيل سالسيليك أسيد)، إذا كنت تتناول أكثر من 3 غرام في اليوم.</p><p dir="RTL">أدوية علاج الاكتئاب و علاج مشاكل الصحة النفسية، بما في ذلك، الليثيوم.</p><p dir="RTL">مكملات البوتاسيوم والبدائل التي تحتوي على البوتاسيوم أو الأدوية الأخرى التي يمكن أن تزيد من البوتاسيوم في الجسم.</p><p dir="RTL">الإنسولين أو أي الأدوية التي يتم تناولها عن طريق الفم لعلاج داء السكري.</p><p dir="RTL">الأدوية التي تستعمل لعلاج السرطان (مثل، إيڤيروليمس) و الأدوية التي تعطى لتجنب رفض الجسم للعضو المزروع، على سبيل المثال، الكلى أو الكبد (مثل، تيمسيروليمس، سيروليمس).</p><p dir="RTL">راسيكادوتريل، يستعمل لعلاج الإسهال.</p><p dir="RTL">منشط الأنسجة البلازمينوجين والذي يستعمل لإذابة جلطات الدم التي تكونت في الأوعية الدموية.</p><p dir="RTL">الأدوية التي تستعمل لعلاج الربو.</p><p dir="RTL">الأدوية التي تستعمل لعلاج احتقان الأنف أو الجيوب الأنفية أو الأدوية الأخرى لعلاج نزلات البرد (بما في ذلك الأدوية التي تستطيع شراؤها من الصيدلية).</p><p dir="RTL">الأدوية التي تثبط استجابة الجسم المناعية (مثبطات المناعة).</p><p dir="RTL">ألوبيورينول (لعلاج النقرس).</p><p dir="RTL">بروكيناميد (لعلاج مشاكل نبضات القلب).</p><p dir="RTL">الأدوية التي تحتوي على الذهب، مثل أوروثيومالات الصوديوم، التي قد تُعطى لك عن طريق الحقن.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك حامل (أو من المتوقع حصول الحمل). سينصحك الطبيب عادة بالتوقف عن تناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>&nbsp;قبل حصول الحمل أو فور العلم بحصوله و سينصحك بتناول دواء آخر بدلاً من <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong>. لا يوصى بتناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>في المراحل الأولى من الحمل، ويجب عدم تناوله إذا كان عمر الحمل يزيد عن 3 أشهر، حيث قد يسبب أذى خطير للجنين عند استعماله بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">أخبري طبيبك إذا كنت مرضعة أو على وشك البدء في الإرضاع. لا يوصى باستعمال <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>&nbsp;للأمهات المرضعات و قد يختار الطبيب علاج آخر لك إذا كنت ترغبين في الإرضاع. خصوصا إذا كان طفلك حديث الولادة، أو ولد قبل أوانه.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>و</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">يشعر بعض الأشخاص بالدوار أو التعب عند تناول هذا الدواء. إذا حدث هذا، تجنب قيادة المركبات أو استخدام أي أدوات او آلات.</p><p dir="RTL">يجب عليك الانتظار لرؤية مدى تأثير الدواء عليك قبل القيام بأي من هذه النشاطات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong> تماما كما أخبرك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">في حال بدأت بتناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong> قد يقوم طبيبك&nbsp; بإجراء فحوصات للدم. قد يقوم طبيبك بعد ذلك بتعديل الجرعة و بذلك سوف تتناول الكمية المناسبة لك من الدواء.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>الدواء</strong></p><p dir="RTL">قم بتناول القرص مع شرب الماء.</p><p dir="RTL">حاول تناول الأقراص بنفس الوقت من كل يوم. لا يهم إذا تناولت <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>قبل تناول الطعام أو بعده.</p><p dir="RTL">استمر في تناول <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong> للمدة التي اخبرك بها طبيبك، وذلك لأنه علاج طويل الأمد. من المهم الاستمرار في تناول <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>كل يوم.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>جرعتك</strong><strong> </strong><strong>الأولى</strong></p><p dir="RTL">عليك توخي الحذرعند تناول الجرعة الأولى من<strong> </strong><strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>&nbsp;أو عند زيادة الجرعة. لأن ذلك قد يؤدي إلى انخفاض كبير في ضغط الدم أكثر من الجرعات التالية.</p><p dir="RTL">قد تشعر بالدوار أو الدوخة. إذا حدث هذا، قد يساعدك الاستلقاء. إذا كنت تشعر بالقلق، يرجى التحدث مع طبيبك في أقرب وقت ممكن.</p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">تعتمد الجرعة على حالتك الصحية و إذا كنت تتناول أي أدوية أخرى. سيخبرك طبيبك عدد الأقراص التي يجب تناولها كل يوم. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكد.</p><p dir="RTL"><strong>لعلاج</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>ضغط</strong><strong> </strong><strong>الدم</strong></p><p dir="RTL">الجرعة الابتدائية الموصى بها هي 10 ملغم مرة واحدة يوميا.</p><p dir="RTL">الجرعة المعتادة على المدى الطويل هي 20 ملغم مرة واحدة يوميا.</p><p dir="RTL"><strong>لعلاج</strong><strong> </strong><strong>قصور</strong><strong> </strong><strong>وظيفة</strong><strong> </strong><strong>القلب</strong></p><p dir="RTL">الجرعة المعتادة على المدى الطويل تتراوح بين 5 إلى 35 ملغم مرة واحدة يوميا.</p><p dir="RTL"><strong>بعد</strong><strong> </strong><strong>الإصابة</strong><strong> </strong><strong>بنوبة</strong><strong> </strong><strong>قلبية</strong></p><p dir="RTL">الجرعة الابتدائية الموصى بها هي 5 ملغم خلال 24 ساعة من الإصابة بالنوبة و 5 ملغم في اليوم الذي يليه.</p><p dir="RTL">الجرعة المعتادة على المدى الطويل هي 10 ملغم مرة واحدة يوميا.</p><p dir="RTL"><strong>لعلاج</strong><strong> </strong><strong>مشاكل</strong><strong> </strong><strong>الكلى</strong><strong> </strong><strong>الناتجة</strong><strong> </strong><strong>عن</strong><strong>&nbsp; </strong><strong>داء</strong><strong> </strong><strong>السكري</strong></p><p dir="RTL">الجرعة الموصى بها هي إما 10 ملغم أو 20 ملغم مرة واحدة يوميا.</p><p dir="RTL">إذا كنت من كبار السن، الذين يعانون من مشاكل في الكلى أو يتناولون أدوية مدرات البول، سيقوم طبيبك بوصف جرعة أقل من الجرعة المعتادة.</p><p dir="RTL"><strong>الاستعمال</strong><strong> </strong><strong>للأطفال</strong><strong> </strong><strong>والمراهقين</strong><strong> (6 </strong><strong>إلى</strong><strong> 16 </strong><strong>سنة</strong><strong>) </strong><strong>و</strong><strong> </strong><strong>يعانون</strong><strong> </strong><strong>من</strong><strong> </strong><strong>ارتفاع</strong><strong> </strong><strong>ضغط</strong><strong> </strong><strong>الدم</strong></p><p dir="RTL">لا يوصى باستعمال <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>للأطفال الأقل من 6 سنوات أو الأطفال الذين يعانون من مشاكل حادة في الكلى.</p><p dir="RTL">سيقوم طبيبك بتحديد الجرعة الصحيحة لطفلك. تعتمد الجرعة على وزن جسم الطفل.</p><p dir="RTL">الأطفال الذين تزيد أوزانهم عن 50 كغم، تبلغ الجرعة الابتدائية المعتادة 5 ملغم مرة واحدة في اليوم.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">إذا تناولت<strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>أكثر من الجرعة التي وصفها طبيبك، تحدث مع طبيبك أو اذهب إلى المستشفى فورا. التأثيرات التالية هي الأكثر احتمالا أن تحدث: الشعور بالدوار، خفقان.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها فور تذكرك. لكن، إذا اقترب موعد الجرعة التالية، تجاوز الجرعة التي نسيتها.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">لا تتوقف عن تناول الأقراص، حتى إذا شعرت بأنك على ما يرام، ما لم يكن يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;إذا كان لديك أي أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب <strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>آثار جانبية، على الرغم من عدم حصولها لدى الجميع.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>التفاعلات</strong><strong> </strong><strong>التالية،</strong><strong> </strong><strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>ليزينوبريل</strong><strong> </strong><strong>و</strong><strong> </strong><strong>اذهب</strong><strong> </strong><strong>لرؤية</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فوراً</strong><strong>:</strong></p><p dir="RTL">تفاعلات تحسسية حادة (نادرة، تؤثر على 1 إلى 10 من كل 10000 مستخدم). قد تتضمن العلامات بداية مفاجئة لما يلي:</p><p dir="RTL">- تورم الوجه، الشفاه، اللسان أو الحلق. قد يسبب هذا صعوبة في البلع.</p><p dir="RTL">- تورم حاد أو مفاجئ في اليدين، القدمين و الكاحلين.</p><p dir="RTL">- صعوبة في التنفس.</p><p dir="RTL">- حكة حادة في الجلد (مع كتل بارزة).</p><p dir="RTL">اضطرابات حادة في الجلد، مثل طفح أو حروق غير متوقعة، احمرار أو تقشير الجلد (نادر جدا، تؤثر على أقل من 1 من كل 10,000 مستخدم).</p><p dir="RTL">التهاب يرافقه أعراض مثل الحمى وتدهور خطير للحالة العامة، أو حمى مع أعراض الالتهابات الموضعية مثل تقرح الحلق/البلعوم/الفم أو مشاكل في المسالك البولية (نادر جدا، تؤثر على أقل من 1 من كل 10,000 مستخدم).</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>محتملة</strong><strong> </strong><strong>أخرى</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>إلى</strong><strong> 10 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>مستخدم</strong><strong>)</strong></p><p dir="RTL">صداع.</p><p dir="RTL">الشعور بالدوار أو دوخة، خاصة عند الوقوف بسرعة.</p><p dir="RTL">إسهال.</p><p dir="RTL">سعال جاف لا يزول.</p><p dir="RTL">قيء.</p><p dir="RTL">مشاكل في الكلى (تظهر في فحوصات الدم).</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>إلى</strong><strong> 10 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>مستخدم</strong><strong>)</strong></p><p dir="RTL">تغيرات في المزاج.</p><p dir="RTL">تغير في لون أصابع اليدين أو القدمين (أزرق شاحب يليه احمرار) أو تنميل أو وخز في أصابع اليدين أو القدمين.</p><p dir="RTL">تغيرات في طريقة تذوق الأشياء.</p><p dir="RTL">الشعور بالنعاس.</p><p dir="RTL">الشعور بالدوران (دوخة).</p><p dir="RTL">صعوبة في النوم.</p><p dir="RTL">سكتة دماغية.</p><p dir="RTL">سرعة في نبضات القلب.</p><p dir="RTL">سيلان الأنف.</p><p dir="RTL">الشعور بالغثيان.</p><p dir="RTL">ألم في المعدة أو عسر الهضم.</p><p dir="RTL">طفح جلدي أو حكة.</p><p dir="RTL">عدم القدرة على الانتصاب عند الرجال (عجز جنسي).</p><p dir="RTL">الشعور بالتعب أو الشعور بالضعف (فقدان القوة).</p><p dir="RTL">انخفاض كبير جداً في ضغط الدم قد يحدث عند الأشخاص الذين يعانون من الحالات التالية:</p><p dir="RTL">مرض القلب التاجي، تضييق الشريان الأبهر(شريان في القلب)، الشريان الكلوي أو صمامات القلب، زيادة في سماكة عضلة القلب. إذا حدث ذلك، قد تشعر بالدوار أو دوخة، خاصة عند الوقوف بسرعة.</p><p dir="RTL">تغيرات في فحوصات الدم التي تبين كفاءة عمل الكبد و الكلى.</p><p dir="RTL">نوبة قلبية.</p><p dir="RTL">رؤية و/أو سماع هلوسات.</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>إلى</strong><strong> 10 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10000 </strong><strong>مستخدم</strong><strong>)</strong></p><p dir="RTL">الشعور بالارتباك.</p><p dir="RTL">طفح بارز عن سطح الجلد (شرى).</p><p dir="RTL">جفاف الفم.</p><p dir="RTL">تساقط الشعر.</p><p dir="RTL">صدفية (مشكلة في الجلد).</p><p dir="RTL">تغير في حاسة الشم.</p><p dir="RTL">نمو الثدي عند الرجال.</p><p dir="RTL">تغيرات في بعض الخلايا أو أجزاء أخرى من الدم. قد يقوم الطبيب بإجراء فحوصات دم من وقت لآخر للتأكد إذا كان لليزينوبريل أي تأثيرعلى الدم. قد تتضمن العلامات الشعور بالتعب، شحوب الجلد، تقرح الحلق، ارتفاع درجة الحرارة (حمى)، ألم المفاصل والعضلات، تورم في المفاصل أو الغدد، أو حساسية لأشعة الشمس.</p><p dir="RTL">انخفاض مستويات الصوديوم في الدم (قد تكون الأعراض الشعور بالتعب، صداع، الشعور بالغثيان، قيء).</p><p dir="RTL">قصور مفاجيء في وظيفة الكلى.</p><p dir="RTL"><strong>نادرة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10,000 </strong><strong>مستخدم</strong><strong>)</strong></p><p dir="RTL">التهاب الجيوب الأنفية (الشعور بالألم و الامتلاء خلف&nbsp; الخدين و العينين).</p><p dir="RTL">أزيز تنفسي.</p><p dir="RTL">انخفاض مستويات السكر في الدم. قد تتضمن العلامات الشعور بالجوع أو الضعف، التعرق وسرعة نبضات القلب.</p><p dir="RTL">&nbsp;التهاب الرئتين. تتضمن العلامات السعال، الشعور بقصر النفس وارتفاع في درجة الحرارة (الحمى).</p><p dir="RTL">اصفرار الجلد أو المنطقة البيضاء في العيون (اليرقان).</p><p dir="RTL">التهاب الكبد. يمكن أن يسبب هذا فقدان الشهية، اصفرار الجلد و العيون و بول داكن اللون.</p><p dir="RTL">التهاب البنكرياس. هذا يسبب ألم متوسط إلى حاد في المعدة.</p><p dir="RTL">اضطرابات حادة في الجلد. تتضمن الأعراض احمرار، تنفط (بثور) و تقشير.</p><p dir="RTL">التعرق.</p><p dir="RTL">التبول أقل من المعتاد أو عدم&nbsp; القدرة على التبول.</p><p dir="RTL">قصور وظيفة الكبد.</p><p dir="RTL">ظهور كتل.</p><p dir="RTL">التهاب الأمعاء</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>معروفة</strong><strong> (</strong><strong>لا</strong><strong> </strong><strong>يمكن</strong><strong> </strong><strong>تقدير</strong><strong> </strong><strong>تكرار</strong><strong> </strong><strong>حدوثها</strong><strong> </strong><strong>من</strong><strong> </strong><strong>البيانات</strong><strong> </strong><strong>المتوفرة</strong><strong>)</strong></p><p dir="RTL">أعراض الاكتئاب.</p><p dir="RTL">إغماء.</p><p dir="RTL">تفاعلات تحسسية خطيرة.</p><p dir="RTL">تبين أن الآثار الجانبية عند الأطفال مشابهة لتلك التي ظهرت عند البالغين.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي،</strong><strong> </strong><strong>و</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>يتضمن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong><strong>. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل<strong> </strong>أقراص <strong>لينوبريل</strong><strong><sup>&reg; </sup></strong>بعد تاريخ انتهاء الصلاحية (EXP) المذكورعلى الشريط و العبوة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>لينوبريل</strong><strong><sup>&reg;</sup></strong><strong> </strong>&nbsp;أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي ليزينوبريل (ثنائي مائي).</p><p dir="RTL">المكونات الأخرى هي مانيتول، هيدروجين فوسفات الكالسيوم، نشا الذرة، نشا مجلتن، ستيرات المغنيسيوم، أكسيد الحديد الأحمر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لينوبريل</strong><strong><sup>&reg; </sup></strong><strong>5 </strong><strong>ملغم</strong><strong> </strong><strong>أقراص</strong>: هي<strong> </strong>أقراص<strong> </strong>ذات لون أحمر قرميدي فاتح، دائرية الشكل، محدبة الوجه، محفور على أحد الأوجه PhI، و خط التقسيم على الوجه الآخر، معبأة في أشرطة بي ڤي سي/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 28 قرص (14 قرص/ شريط، 2 شريط/عبوة).</p><p dir="RTL"><strong>لينوبريل</strong><strong><sup>&reg; </sup></strong><strong>10 </strong><strong>ملغم</strong> <strong>أقراص</strong><strong>:</strong> هي أقراص<strong> </strong>ذات لون أحمر قرميدي، دائرية الشكل، محدبة الوجه، محفور على أحد الأوجه PhI، و خط التقسيم على الوجه الآخر، معبأة في أشرطة بي ڤي سي/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 28 قرص (14 قرص/ شريط، 2 شريط/عبوة).</p><p dir="RTL"><strong>لينوبريل</strong><strong><sup>&reg; </sup></strong><strong>20 </strong><strong>ملغم</strong> <strong>أقراص</strong><strong>:</strong> هي أقراص<strong> </strong>ذات لون أحمر، دائرية الشكل، محدبة الوجه، محفور على أحد الأوجه PhI، و خط التقسيم على الوجه الأخر، معبأه في أشرطة بي ڤي سي/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 28 قرص (14 قرص/ شريط، 2 شريط/عبوة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>المملكة</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull;</strong><strong>الإمارات</strong><strong> </strong><strong>العربية</strong><strong> </strong><strong>المتحدة</strong><strong>:</strong></p><p dir="RTL">قسم اليقظة الدوائية والأجهزة الطبية</p><p dir="RTL">ص.ب: 1853، هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">قسم الأدوية، وزارة الصحة و وقاية المجتمع</p><p dir="RTL">دبي- الإمارات العربية المتحدة.</p><p dir="RTL"><strong>&bull; </strong><strong>دول</strong><strong> </strong><strong>الخليج</strong><strong> </strong><strong>العربي</strong><strong> </strong><strong>الأخرى</strong><strong>:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التسويق</strong><strong> </strong><strong>والشركة</strong><strong> </strong><strong>المصنعة</strong><strong>:</strong></p><p dir="RTL">الشركة الدولية للدواء</p><p dir="RTL">عمان &ndash; الأردن</p><p dir="RTL">الهاتف: 5157893 / 5158890 - 6 - 00962&nbsp;</p><p dir="RTL">فاكس:&nbsp; 5154753 - 6 - 00962</p><p dir="RTL">البريد الإلكتروني: marketing@pic-jo.com</p><p dir="RTL"><br />هذه النشرة لا تحتوي على جميع المعلومات عن المستحضر. إذا كان لديك أية أسئلة أو لم تكن متأكدا من أي شيء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL" style="margin-left:0cm; margin-right:0cm; text-align:right"><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح هذه النشرة في 10 /2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Linopril® 5mg Tablets
Linopril® 10 mg Tablets
Linopril® 20mg Tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Linopril® 5mg Tablets: Each tablet contains lisinopril dihydrate equivalent to 5 mg anhydrous lisinopril.
Linopril® 10mg Tablets: Each tablet contains lisinopril dihydrate equivalent to 10 mg anhydrous lisinopril.
Linopril® 20mg Tablets: Each tablet contains lisinopril dihydrate equivalent to 20 mg anhydrous lisinopril.
 
Excipient: 
 For a full list of excipients: see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Linopril® 5mg Tablets: Light red brick, round, normal convex tablet engraved with PhI on one face and scored on the other, packed in PVC/ Alu blisters, intended for oral use.
Linopril® 10mg Tablets: Red brick, round, normal convex tablet engraved with PhI on one face and scored on the other, packed in PVC/ Alu blisters, intended for oral use.
Linopril® 20mg Tablets: Red brick, round; normal convex tablets engraved with PhI on one side and plain on the other, packed in PVC/ Alu blisters, intended for oral use.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypertension</strong></p><p>Treatment of hypertension.</p><p><strong>Heart failure</strong></p><p>Treatment of symptomatic heart failure.</p><p><strong>Acute myocardial infarction</strong></p><p>Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction.</p><p><strong>Renal complications of diabetes mellitus</strong></p><p>Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Linopril</strong><sup>&reg;</sup> should be administered orally in a single daily dose. As with all other medication taken once daily, <strong>Linopril</strong><sup>&reg;</sup> should be taken at approximately the same time each day. The absorption of <strong>Linopril</strong><sup>&reg;</sup> tablets is not affected by food.</p><p>The dose should be individualised according to patient profile and blood pressure response (see section 4.4).</p><p><strong>Hypertension</strong></p><p><strong>Linopril</strong><sup>&reg;</sup> may be used as monotherapy or in combination with other classes of antihypertensive therapy.</p><p><strong><u>Starting dose</u></strong></p><p>In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 2.5‑5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. A lower starting dose is required in the presence of renal impairment (see Table 1 below).</p><p><strong><u>Maintenance dose</u></strong></p><p>The usual effective maintenance dosage is 20 mg administered in a single daily dose. In general, if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level, the dose can be further increased. The maximum dose used in long-term, controlled clinical trials was 80 mg/day.</p><p><strong><u>Diuretic-treated patients</u></strong></p><p>Symptomatic hypotension may occur following initiation of therapy with <strong>Linopril</strong><sup>&reg;</sup>. This is more likely in patients who are being treated currently with diuretics. Caution is recommended therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with <strong>Linopril</strong><sup>&reg;</sup>. In hypertensive patients in whom the diuretic cannot be discontinued, therapy with <strong>Linopril</strong><sup>&reg;</sup> should be initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of <strong>Linopril</strong><sup>&reg;</sup> should be adjusted according to blood pressure response. If required, diuretic therapy may be resumed (see section 4.4 and section 4.5).</p><p><strong><u>Dosage adjustment in renal impairment</u></strong></p><p>Dosage in patients with renal impairment should be based on creatinine clearance as outlined in Table 1 below.</p><p><strong>Table 1 Dosage adjustment in renal impairment</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Starting Dose (mg/day)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Less than 10 ml/min (including patients on dialysis)</p></td><td style="vertical-align:top"><p>2.5 mg*</p></td></tr><tr><td style="vertical-align:top"><p>10‑30 ml/min</p></td><td style="vertical-align:top"><p>2.5‑5 mg</p></td></tr><tr><td style="vertical-align:top"><p>31‑80 ml/min</p></td><td style="vertical-align:top"><p>5‑10 mg</p></td></tr></tbody></table><p>* Dosage and/or frequency of administration should be adjusted depending on the blood pressure response.</p><p>The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.</p><p><strong><u>Use in hypertensive paediatric patients aged 6&ndash;16 years</u></strong></p><p>The recommended initial dose is 2.5 mg once daily in patients 20 to &lt;50 kg, and 5 mg once daily in patients &ge;50 kg. The dosage should be individually adjusted to a maximum of 20 mg daily in patients weighing 20 to &lt;50 kg, and 40 mg in patients &ge;50 kg. Doses above 0.61 mg/kg (or in excess of 40 mg) have not been studied in paediatric patients (see section 5.1).</p><p>In children with decreased renal function, a lower starting dose or increased dosing interval should be considered.</p><p><strong>Heart failure</strong></p><p>In patients with symptomatic heart failure, <strong>Linopril</strong><sup>&reg;</sup> should be used as adjunctive therapy to diuretics and, where appropriate, digitalis or beta-blockers. <strong>Linopril</strong><sup>&reg;</sup> may be initiated at a starting dose of 2.5 mg once a day, which should be administered under medical supervision to determine the initial effect on the blood pressure. The dose of<strong> Linopril</strong><sup>&reg;</sup> should be increased:</p><p>&bull; By increments of no greater than 10 mg.</p><p>&bull; At intervals of no less than 2 weeks.</p><p>&bull; To the highest dose tolerated by the patient up to a maximum of 35 mg once daily.</p><p>Dose adjustment should be based on the clinical response of individual patients.</p><p>Patients at high risk of symptomatic hypotension, e.g. patients with salt depletion with or without hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy with <strong>Linopril</strong><sup>&reg;</sup>. Renal function and serum potassium should be monitored (see section 4.4).</p><p><strong>Acute myocardial infarction</strong></p><p>Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may be used together with<strong> Linopril</strong><sup>&reg;</sup>.</p><p><strong><u>Starting dose (first 3 days after infarction)</u></strong></p><p>Treatment with <strong>Linopril</strong><sup>&reg;</sup> may be started within 24 hours of the onset of symptoms. Treatment should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of <strong>Linopril</strong><sup>&reg;</sup> is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when treatment is started or during the first 3 days after the infarction should be given a lower dose - 2.5 mg orally (see section 4.4).</p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial <strong>Linopril</strong><sup>&reg;</sup> dosage should be adjusted according to the patient&#39;s creatinine clearance (see Table 1).</p><p><strong><u>Maintenance dose</u></strong></p><p>The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less than 90 mm Hg for more than 1 hour)<strong> Linopril</strong><sup>&reg;</sup> should be withdrawn.</p><p>Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients who develop symptoms of heart failure should continue with <strong>Linopril</strong><sup>&reg;</sup> (see section 4.2).</p><p><strong>Renal complications of diabetes mellitus</strong></p><p>In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 10 mg <strong>Linopril</strong><sup>&reg;</sup> once daily which can be increased to 20 mg once daily, if necessary, to achieve a sitting diastolic blood pressure below 90 mm Hg.</p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial <strong>Linopril</strong><sup>&reg; </sup>dosage should be adjusted according to the patient&#39;s creatinine clearance (see Table 1).</p><p><strong>Paediatric use</strong></p><p>There is limited efficacy and safety experience in hypertensive children&gt;6 years old, but no experience in other indications (see section 5.1). <strong>Linopril</strong><sup>&reg;</sup> is not recommended in children in other indications than hypertension.</p><p><strong>Linopril</strong><sup>&reg;</sup> is not recommended in children below the age of 6, or in children with severe renal impairment (GFR &lt;30ml/min/1.73m<sup>2</sup>) (see section 5.2).</p><p><strong>Older people</strong></p><p>In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. When advanced age is associated with decrease in renal function, however, the guidelines set out in Table 1 should be used to determine the starting dose of <strong>Linopril</strong><sup>&reg;</sup>. Thereafter, the dosage should be adjusted according to the blood pressure response.</p><p><strong>Use in kidney transplant patients</strong></p><p>There is no experience regarding the administration of <strong>Linopril</strong><sup>&reg;</sup> in patients with recent kidney transplantation. Treatment with <strong>Linopril</strong><sup>&reg;</sup> is therefore not recommended.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to Linopril®, to any of the excipients listed in section 6.1 or any other angiotensin converting enzyme (ACE) inhibitor.
•	History of anaphylactic/anaphylactoid reactions or angioedema associated with previous ACE inhibitor therapy.
•	Hereditary or idiopathic angioedema.
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
•	In combination with aliskiren-containing medicines in patients with diabetes mellitus (type I or II) or with moderate to severe renal impairment (GFR < 60ml/min/1.73m2).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Symptomatic hypotension</strong></p><p>Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In hypertensive patients receiving Lisinopril, hypotension is more likely to occur if the patient has been volume-depleted, e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored. Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with Lisinopril. This effect is anticipated and is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or discontinuation of Lisinopril may be necessary.</p><p><strong>Hypotension in acute myocardial infarction</strong></p><p>Treatment with Lisinopril must not be initiated in acute myocardial infarction patients who are at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These are patients with systolic blood pressure of 100 mm Hg or lower, or those in cardiogenic shock. During the first 3 days following the infarction, the dose should be reduced if the systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Lisinopril should be withdrawn.</p><p><strong>Aortic and mitral valve stenosis / hypertrophic cardiomyopathy</strong></p><p>As with other ACE inhibitors, Lisinopril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.</p><p><strong>Renal function impairment</strong></p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Lisinopril dosage should be adjusted according to the patient&#39;s creatinine clearance (see Table 1 in section 4.2), and then as a function of the patient&#39;s response to treatment. Routine monitoring of potassium and creatinine is part of normal medical practice for these patients.</p><p>In patients with heart failure, hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function. Acute renal failure, usually reversible, has been reported in this situation.</p><p>In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a solitary kidney, who have been treated with angiotensin-converting enzyme inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, treatment should be started under close medical supervision with low doses and careful dose titration. Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of Lisinopril therapy.</p><p>Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when Lisinopril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Lisinopril may be required.</p><p>In acute myocardial infarction, treatment with Lisinopril should not be initiated in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during treatment with Lisinopril (serum creatinine concentration exceeding 265 micromol/l or a doubling from the pre-treatment value) then the physician should consider withdrawal of Lisinopril.</p><p><strong>Hypersensitivity/Angioedema</strong></p><p>Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin-converting enzyme inhibitors, including Lisinopril. This may occur at any time during therapy. In such cases, Lisinopril should be discontinued promptly and appropriate treatment and monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patients. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.</p><p>Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to experience airway obstruction, especially those with a history of airway surgery. In such cases emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patient&#39;s airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.</p><p>Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p>Some drugs if given concomitantly with ACE inhibitors may increase the risk of angioedema (see section 4.5)</p><p><strong>Anaphylactoid reactions in haemodialysis patients</strong></p><p>Anaphylactoid reactions have been reported in patients dialysed with high flux membranes (e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients, consideration should be given to using a different type of dialysis membrane or different class of antihypertensive agent.</p><p><strong>Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis</strong></p><p>Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p><strong>Desensitisation</strong></p><p>Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have sustained anaphylactoid reactions. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld but they have reappeared upon inadvertent re-administration of the medicinal product.</p><p><strong>Hepatic failure</strong></p><p>Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving Lisinopril who develop jaundice or marked elevations of hepatic enzymes should discontinue Lisinopril and receive appropriate medical follow-up.</p><p><strong>Neutropenia/Agranulocytosis</strong></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after discontinuation of the ACE inhibitor. Lisinopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If Lisinopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.</p><p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with aliskiren containing medicine</strong></p><p>There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong>Race</strong></p><p>ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>As with other ACE inhibitors, Lisinopril may be less effective in lowering blood pressure in black patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p><strong>Cough</strong></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p><strong>Surgery/Anaesthesia</strong></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Lisinopril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p><strong>Hyperkalaemia</strong></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including <strong>Linopril</strong><sup>&reg;</sup>. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those patients taking other drugs associated with increases in serum potassium (e.g. heparin). If concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of serum potassium is recommended (see section 4.5).</p><p><strong>Diabetic patients</strong></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 Interaction with other medicinal products and other forms of interaction).</p><p><strong>Lithium</strong></p><p>The combination of lithium and Lisinopril is generally not recommended (see section 4.5).</p><p><strong>Pregnancy</strong></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Antihypertensive agents</strong></p><p>When <strong>Linopril</strong><sup>&reg;</sup> is combined with other antihypertensive agents (e.g. glyceryl trinitrate and other nitrates, or other vasodilators), additive falls in blood pressure may occur.</p><p>Clinical trial data has shown that dual blockade of (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal&nbsp;function (including acute renal failure) compared to the use of a single RAAS-acting agent.</p><p>Drugs that may increase the risk of angioedema Concomitant treatment of ACE inhibitors with mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus, sirolimus, everolimus) or neutral endopeptidase (NEP) inhibitors (e.g. racecadotril) 5 or tissue plasminogen activator may increase the risk of angioedema.</p><p><strong>Diuretics</strong></p><p>When a diuretic is added to the therapy of a patient receiving <strong>Linopril</strong><sup>&reg;</sup> the antihypertensive effect is usually additive.</p><p>Patients already on diuretics and especially those, in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure when <strong>Linopril</strong><sup>&reg;</sup> is added. The possibility of symptomatic hypotension with <strong>Linopril</strong><sup>&reg;</sup> can be minimised by discontinuing the diuretic prior to initiation of treatment with <strong>Linopril</strong><sup>&reg;</sup> (see section 4.4 and section 4.2).</p><p><strong>Potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes and other drugs that may increase serum potassium levels</strong></p><p>Although in clinical trials, serum potassium usually remained within normal limits, hyperkalaemia did occur in some patients. Risk factors for the development of hyperkalaemia include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes other drugs that may increase serum potassium levels (heparin, co-trimoxazole) The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes and other drugs that may increase serum potassium levels, particularly in patients with impaired renal function, may lead to a significant increase in serum potassium. If <strong>Linopril</strong><sup>&reg; </sup>is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be ameliorated.</p><p><strong>Lithium</strong></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased lithium toxicity with ACE inhibitors. Use of <strong>Linopril</strong><sup>&reg;</sup> with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p><strong>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid &ge; 3 g/day</strong></p><p>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. These effects are usually reversible. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><strong>Gold</strong></p><p>Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example, sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.</p><p><strong>Tricyclic antidepressants / Antipsychotics / Anaesthetics</strong></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p><strong>Sympathomimetics</strong></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p><strong>Antidiabetics</strong></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood glucose-lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p><strong>Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates</strong></p><p><strong>Linopril</strong><sup>&reg;</sup> may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics, beta-blockers and/or nitrates.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0"><tbody><tr><td><p><strong>Pregnancy</strong></p><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitors therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</p><p>Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><strong>Breastfeeding</strong></p><p>Because no information is available regarding the use of <strong>Linopril</strong><sup>&reg;</sup> during breast-feeding, <strong>Linopril</strong><sup>&reg;</sup> is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0"><tbody><tr><td><p>The following undesirable effects have been observed and reported during treatment with lisinopril and other ACE inhibitors with the following frequencies: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Decreases in haemoglobin, decreases in haematocrit.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Bone marrow depression, anaemia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia, lymphadenopathy, autoimmune disease.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hypoglycaemia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system and psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dizziness, headache.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Mood alterations, paraesthesia, vertigo, taste disturbance, sleep disturbances, hallucination.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Mental confusion, olfactory disturbance.</p></td></tr><tr><td style="vertical-align:top"><p>Frequency not known:</p></td><td style="vertical-align:top"><p>Depressive symptoms, syncope.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac and vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Orthostatic effects (including hypotension)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see section 4.4), palpitations, tachycardia, Raynaud&#39;s phenomenon.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Rhinitis</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>diarrhea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>nausea, abdominal pain and indigestion</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or cholestatic, jaundice and hepatic failure (see section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>urticaria, alopecia, psoriasis, hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>sweating, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, cutaneous pseudolymphoma.</p></td></tr></tbody></table><p>A symptom complex has been reported which may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies (ANA), elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological manifestations may occur.</p><table border="0" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>renal dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>uraemia, acute renal failure</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>oliguria/ anuria.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Impotence</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Gynaecomastia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fatigue, asthenia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increases in blood urea, increases in serum creatinine, increases in liver enzymes, hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Increases in serum bilirubin, hyponatraemia.</p></td></tr></tbody></table><p>Safety data from clinical studies suggest that lisinopril is generally well tolerated in hypertensive paediatric patients and that the safety profile in this age group is comparable to that seen in adults.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>&bull;United Arab of Emirates:</strong></p><p>Pharmacovigilance and Medical Device Section</p><p>P.O. Box: 1853, Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department, Ministry of Health &amp; Prevention</p><p>Dubai-UAE.</p><p><strong>&bull;Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Limited data are available for overdose in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.</p><p>The recommended treatment of overdose is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating <strong>Linopril</strong><sup>&reg;</sup> (e.g. emesis, gastric lavage, administration of absorbents and sodium sulphate). <strong>Linopril</strong><sup>&reg;</sup> may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored frequently.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0"><tbody><tr><td><p>Pharmacotherapeutic group: Angiotensin-converting enzyme inhibitors, ATC code: C09A A03.</p><p><strong><u>Mechanism of Action&nbsp;&nbsp; </u></strong></p><p><strong>Linopril</strong><sup>&reg;</sup> is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may result in an increase in serum potassium concentration.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>The effect of Lisinopril on mortality and morbidity in heart failure has been studied by comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once daily). In a study of 3164 patients, with a median follow-up period of 46 months for surviving patients, high dose Lisinopril produced a 12% risk reduction in the combined endpoint of all-cause mortality and all-cause hospitalization (p = 0.002) and an 8% risk reduction in all-cause mortality and cardiovascular hospitalization (p = 0.036) compared with low dose. Risk reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 0.073) were observed. In a post-hoc analysis, the number of hospitalizations for heart failure was reduced by 24% (p=0.002) in patients treated with high-dose<strong> </strong>Lisinopril compared with low dose. Symptomatic benefits were similar in patients treated with high and low doses of Lisinopril.</p><p>The results of the study showed that the overall adverse event profiles for patients treated with high or low dose Lisinopril were similar in both nature and number. Predictable events resulting from ACE inhibition, such as hypotension or altered renal function, were manageable and rarely led to treatment withdrawal. Cough was less frequent in patients treated with high dose Lisinopril compared with low dose.</p><p>In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Lisinopril and glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394 patients who were administered the treatment within 24 hours of an acute myocardial infarction, Lisinopril produced a statistically significant risk reduction in mortality of 11% versus control (2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination of Lisinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% versus control (2p=0.02). In the sub-groups of elderly (age&gt; 70 years) and females, pre-defined as patients at high risk of mortality, significant benefit was observed for a combined endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as the high-risk sub-groups at 6 months, also showed significant benefit for those treated with Lisinopril or Lisinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for Lisinopril. As would be expected from any vasodilator treatment, increased incidences of hypotension and renal dysfunction were associated with Lisinopril treatment but these were not associated with a proportional increase in mortality.</p><p>In a double-blind, randomized, multicenter trial which compared Lisinopril with a calcium channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient nephropathy characterized by micro-albuminuria, Lisinopril 10 mg to 20 mg administered once daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary albumin excretion rate by 40%. When compared with the calcium channel blocker, which produced a similar reduction in blood pressure, those treated with Lisinopril showed a significantly greater reduction in urinary albumin excretion rate, providing evidence that the ACE inhibitory action of Lisinopril reduced micro-albuminuria by a direct mechanism on renal tissues in addition to its blood pressure-lowering effect.</p><p>Lisinopril treatment does not affect glycemic control as shown by a lack of significant effect on levels of glycated hemoglobin (HbA<sub>1c</sub>).</p><p><strong><u>Pediatric population</u></strong></p><p>In a clinical study involving 115 pediatric patients with hypertension, aged 6&ndash;16 years, patients who weighed less than 50 kg received either 0.625 mg, 2.5 mg or 20 mg of Lisinopril once a day, and patients who weighed 50 kg or more received either 1.25 mg, 5 mg or 40 mg of Lisinopril once a day. At the end of 2 weeks, Lisinopril administered once daily lowered trough blood pressure in a dose-dependent manner with a consistent antihypertensive efficacy demonstrated at doses greater than 1.25 mg.</p><p>This effect was confirmed in a withdrawal phase, where the diastolic pressure rose by about 9 mm Hg more in patients randomized to placebo than it did in patients who were randomized to remain on the middle and high doses of Lisinopril. The dose-dependent antihypertensive effect of Lisinopril was consistent across several demographic subgroups: age, Tanner stage, gender, and race.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.</p><p><strong>Absorption</strong></p><p>Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 16% in patients with heart failure. Lisinopril absorption is not affected by the presence of food.</p><p><strong>Distribution</strong></p><p>Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin-converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.</p><p><strong>Elimination</strong></p><p>Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. On multiple dosing, lisinopril has an effective half-life of accumulation of 12.6 hours. The clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose.</p><p><strong>Hepatic impairment</strong></p><p>Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption (about 30% as determined by urinary recovery), but an increase in exposure (approximately 50%) compared to healthy subjects due to decreased clearance.</p><p><strong>Renal impairment</strong></p><p>Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min), mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed in severe renal impairment (creatinine clearance 5-30 ml/min).</p><p>Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 ml/min.</p><p><strong>Heart failure</strong></p><p>Patients with heart failure have a greater exposure of lisinopril when compared to healthy subjects (an increase in AUC on average of 125%), but based on the urinary recovery of lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.</p><p><strong>Paediatric population</strong></p><p>The pharmacokinetic profile of lisinopril was studied in 29 paediatric hypertensive patients, aged between 6 and 16 years, with a GFR above 30 ml/min/1.73m2. After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours, and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults.</p><p>AUC and Cmax&nbsp;values in children in this study were consistent with those observed in adults.</p><p><strong>Elderly</strong></p><p>Elderly have higher blood levels and higher values for the area under the plasma concentration-time curve (increased approximately 60%) compared with younger subjects.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0"><tbody><tr><td><p>Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin-converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late fetal development, resulting in fetal death and congenital effects, in particular affecting the skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also been reported. These developmental anomalies are thought to be partly due to a direct action of ACE inhibitors on the fetal renin-angiotensin system and partly due to ischemia resulting from maternal hypotension and decreases in fetal-placental blood flow and oxygen/nutrients delivery to the fetus.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol, calcium hydrogen phosphate, maize starch, pregelatinised starch, magnesium stearate, red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Linopril<sup>&reg;</sup></strong> 5mg Tablets: Light red brick, round, normal convex tablet engraved with PhI on one face and scored on the other, packed in PVC/ Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 28 Tablets (14 tablets/blister, 2 blisters/pack).</p><p><strong>Linopril<sup>&reg;</sup></strong> 10mg Tablets: Red brick, round, normal convex tablet engraved with PhI on one face and scored on the other, packed in PVC/ Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 28 Tablets (14 tablets/blister, 2 blisters/pack).</p><p><strong>Linopril<sup>&reg;</sup></strong> 20mg Tablets: Red brick, round; normal convex tablets engraved with PhI on one side and plain on the other, packed in PVC/ Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 28 Tablets (14 tablets/blister, 2 blisters/pack).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:left">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma International Company
Amman - Jordan
Tel: 00962-6-5158890 / 5157893 
Fax: 00962-6-5154753
Email: marketing@pic-jo.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>